The Nox1/Nox4 inhibitor attenuates acute lung injury induced by ischemia-reperfusion in mice

Yu Cui¹,²*, Yu Wang³, Gen Li⁴, Wan Ma¹, Xiao-shuang Zhou¹, Jia Wang¹, Bin Liu¹

¹ Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China, ² Department of Anesthesiology, Chengdu Women's and Children's Central Hospital, Chengdu, Sichuan, China, ³ Department of Anesthesiology, No.363 Hospital, Chengdu, Sichuan, China, ⁴ Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America

* These authors contributed equally to this work.
‡ These authors share first authorship on this work.

Abstract

Lung ischemia and reperfusion injury (LIRI) were mediated by several processes including over-production of reactive oxygen species (ROS) and inflammatory activation. ROS generated by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Nox) may play a pivotal role in pathophysiological changes in a range of disease. However, it was poorly understood in LIRI. Thus, the purpose of our study was to explore whether GKT137831, as a special dual inhibitor of Nox1 and 4, could alleviate LIRI in mice model and explore the minimal dose. According to the protocol, this study was divided into two parts. The first part was to determine the minimal dose of Nox1/4 inhibitor in attenuating LIRI via histopathology and apoptosis analysis. Eighteen C57BL/6J male wild-type mice were randomly divided into sham, 2.5Nox+sham, 5.0Nox+sham, IR, 2.5Nox+IR and 5.0Nox+IR groups. According to the different group, mice were pretreated with corresponding dose of Nox1/4 inhibitors or normal saline. After LIRI, the results showed 5.0mg/kg Nox1/4 inhibitor could be considered as the minimal dose to alleviate injury by decreasing of lung injury score and the number of TUNEL-positive cells. The second part was to further verify the benefit of 5.0mg/kg Nox1/4 inhibitor in lung protective effects. Thirty-seven C57BL/6J male wild-type mice were divided in to sham, IR and 5.0Nox+IR groups randomly. The results showed that expressions of inflammatory, autophagy cytokines were markedly elevated and PH value was declined after LIRI. However, 5.0 mg/kg Nox1/4 inhibitor significantly attenuated cytokine production as reflected by immunohistochemistry, western blotting and Q-PCR analysis. In conclusion, our findings suggested that 5.0mg/kg Nox1/4 inhibitor contributed to protect lung tissue damage after LIRI via the suppression of inflammatory and autophagy activation.

1. Introduction

Lung ischemia reperfusion injury (LIRI), a severe complication which may lead to high morbidity and mortality, is defined as a temporary arrest of ventilation and/or blood supply in at
least one lung [1] and paradoxically exacerbates further damage and dysfunction with re-establishment of reperfusion and reoxygenation [2]. LIRI, mainly occurs in lung transplantation or cardiopulmonary bypass, still is one of the greatest challenges in postoperative care, as it can lead to acute lung injury (ALI), even more severe lethal complications such as adult respiratory distress syndrome (ARDS) [3]. A previous animal research demonstrated that no matter short- or long-term changes after LIRI in rats were similar to the changes in ARDS and primary graft dysfunction (PGD) after lung transplantation [4]. Clearly, to date, the current measures are mainly on supportive rather than prophylaxis, and there is no effective method or drug to avoid its occurrence in clinical practice.

While LIRI was a complex process, recent research had highlighted the importance in oxidative stress responses, inflammation [1, 5], innate immune responses [2, 6, 7] and endothelial barrier function [2, 7]. When an organ began to suffer hypoxia or ischemia, a series of cascade reactions would be initiated. Although by now no convincing evidence had shown which was the most critical event for tissue damage, increasing evidence suggested that ischemia-reperfusion injury was related to form reactive oxygen species (ROS) [8–10]. Due to the increasing of ROS, the inflammatory process was activated and exacerbated, such as releasing inflammatory cytokines, increasing vascular permeability, platelet aggregation of neutrophils, the occurrence of sterile inflammation, activation of cytokines and the complement system, which had been well summarized previously [11].

NADPH oxidase enzyme (Nox) distributed in tissues and organs widely, which was a membrane protein consisting seven family members (Nox1-5 and Duox1-2), [12]. Increasing evidence had shown that Nox family members took part in a wide range of diseases by producing excess ROS, especially Nox1, Nox2 and Nox4 [13]. Previous reviews had elucidated the structure and function clearly [12, 14, 15]. Recent studies had shown that Nox1 and Nox4 incriminated in inflammation progressing by activating oxidative stress [16, 17].

Therefore, we hypothesize that Nox1/4 inhibitor can alleviate LIRI-associated inflammation, autophagy events and innate immunity. Thus, we conduct the research in mice. We determine the minimal dose of Nox1/4 inhibitors which can attenuate LIRI. We also test the changes of inflammatory and autophagy cytokines expression, cell apoptosis in vivo and measure tissue levels of innate immune response cytokines including interferon-α/β.

2. Materials and methods

2.1 Nox1/4 inhibitor

GKT137831 was provided by Genkyotex S.A, Geneva, Switzerland, which was a special and efficient dual inhibitor of Nox1/4. It was a pyrazolopyridine dione core inhibitor of the enzymatic activity describing recently, and applied for reducing inflammation in the ischemic retina [18]. In previous research, Nox1/4 inhibitor, GKT137831, was dissolved in normal saline solution, and 60 mg/kg body weight was injected subcutaneously [18]. Thus, in our experiment, GKT137831 was used as Nox1/4 inhibitor.

2.2 Animals

Male C57BL/6j wild-type (WT) mice (6–8 weeks old and weighing 20–25 g) were purchased from Sichuan Provincial Laboratory Animal Public Service Center (Chengdu, China). The mice were cured without restriction of water and food in the West China Hospital Laboratory Center. Room temperature and humidity maintained 22 ± 2°C and 55% ± 15% respectively and the light/dark cycle alternated 12:12 hours. This experiment was authorized by the Animal Ethics Committee at West China Hospital of Sichuan University, and the procedure was also supervised under this committee.
2.3 Experimental protocol and lung I/R model

The study had been divided into two parts. The first part was to verify whether Nox1/4 inhibitor could alleviate LIRI and determine the minimal dose of Nox1/4 inhibitor by histological and apoptosis analysis. The second part was to find further molecular evidence to determine the minimal dose of Nox1/4 inhibitor could attenuate LIRI.

2.3.1 Grouping. In the first part, C57BL/6J WT mice were allocated to six groups randomly: Group 1 (sham group, n = 3); Group 2 [2.5mg/kg Nox1/4 inhibitors pretreatment group(2.5Nox+sham, n = 3)]; Group 3 [5mg/kg Nox1/4 inhibitors pretreatment group(5.0Nox +sham, n = 3)]; Group 4 (IR group, n = 3); Group 5 [2.5mg/kg Nox1/4 inhibitors pretreatment + IR group (2.5Nox+IR group, n = 3)] and Group 6 (5mg/kg Nox1/4 inhibitors pretreatment group+IR (5.0Nox+IR group, n = 3)].

In the second part, only three group were enrolled, including sham group (n = 12), IR group (n = 12), and 5.0Nox+IR group (n = 13), since we had determined the minimal effective dose.

2.3.2 Experimental protocol. According to different groups, each mouse was pretreated with different dose of Nox1/4 or normal saline, 30min ahead of clamp pulmonary hilum. The Nox1/4 and normal saline were kept in same volume. Anesthetized mice (Intraperitoneal injection of 10% chloral hydrate 0.3 ml/100 g +Fentanyl 0.03mg/kg) were intubated via tracheotomy with 20-guage and mechanically ventilated with FiO$_2$ 0.4 by a small animal Minivent (Harvard Apparatus). The setting of respiratory rate was 120 bpm and tidal volume was 200 μL with body temperature at 36.5–37.4˚C. Following a left 3-4th lateral intercostal space thoracotomy, 100 U/kg heparin (Qianhong, Changzhou, China) was administrated by intra-peritoneal injection. Five minutes later, the left pulmonary hilum, including bronchus, pulmonary artery and vein, was clamped for 60 minutes with a noninvasive micro-vascular clip. Then, the clip was removed in order to re-establish in blood and ventilation for another 120 minutes. The same procedure was performed in the corresponding sham group without clamping pulmonary hilum. After 180 min, arterial blood was drawn from the left ventricle directly. Then mice were euthanized using cervical dislocation under deep anesthesia which was recommended by AVMA [19], and the left lung would be harvested.

2.4 Histopathology of lung tissue analysis

Eighteen mice were used to determinate the minimal dose of Nox1/4 inhibitor for alleviating LIRI in six groups (sham, 2.5mg/kg+sham, 5.0mg/kg+sham, IR, 2.5mg/kg+IR, 5.0mg/kg+IR) by histological and apoptosis analysis.

The upper lobes of left lung were fixed in 4% formaldehyde for 24 h, and sent to pathological experiment lab of Sichuan University (Chengdu, China) where the specimen were embedded in paraffin wax, sliced and stained with H&E. Two investigators who were blinded to the grouping completed the histological analysis following the standard of lung injury score [20, 21] under microscope respectively. The final score was determined by the average of two investigators. Briefly, the injury score system was divided into five levels, range from 0(no damage) to 4(severe damage) basing on severity, including alveolar congestion, hemorrhage, interstitial edema, neutrophil count and alveolar wall thickness [20, 21].

2.5 Apoptosis analysis

The apoptosis analysis, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), was conducted according to the manufacturer’s instruction (Millipore, Sigma, Unite States). TUNEL-positive cells with brown color nuclei were counted under the light
microscope (×400, Olympus, Japan) by the same investigator who was blinded to the grouping.

### 2.6 Optimal dose of Nox1/4 inhibitor determination

Histopathologic and apoptosis evaluation indicated that 5mg/kg Nox1/4 inhibitor pretreatment could be considered the minimal dose in attenuating LIRI (Fig 1A–1D).

After that, another thirty-seven C57BL/6J WT mice were performed for further analysis. They were randomly divided into three groups (sham = 12, IR = 12, 5.0Nox+IR = 13). The mice were allocated to 5.0 Nox+IR group, and then pretreated with 5.0mg/kg Nox1/4 inhibitor

---

**Fig 1. Effects of Nox1/4 inhibitor with different dose pretreatment on LIRI.** (A) Representative photomicrographs in HE staining (×400). (B) Histological lung injury was scored as described in the Materials and Methods sections. (C) Lung epithelial cell apoptosis in mice submitted to LIRI. (D) Representative photomicrographs show TUNEL-positive cells (×40).

Data were expressed as Mean ± SD (n = 3) and compared by one-way ANOVA; **** P<0.0001 vs. sham, 2.5Nox+sham, 5.0Nox+sham group; #### P<0.0001 vs. 5.0Nox+IR group.

[https://doi.org/10.1371/journal.pone.0209444.g001](https://doi.org/10.1371/journal.pone.0209444.g001)
30 minutes before ischemia. The same procedure was conducted in the sham group with pre-treatment of normal saline without clamping pulmonary hilum, and in IR group without any pretreatment (Fig 2).

2.7 Arterial blood gas (ABG) analysis

At the end of the procedure, arterial blood was drawn from the left ventricle directly. Then, PH value and PO$_2$/FiO$_2$ were immediately analyzed by blood gas analyser (Mindray, Shenzhen, China).

2.8 Immunohistochemistry analysis

According to the reporting method [22], the nuclear factor-κBp65(NF-κBp65) and TNF-α were analyzed by immunohistochemistry. After embedded, sliced, deparaffinized and washed, the 4–5μm-thick sections were incubated with the rabbit polyclonal anti-NF-κBp65 antibody (catalog no ab16502, 1:500, Abcam, Cambridge,UK) and TNF-α (catalog no ab6671, 1:100, Abcam, Cambridge,UK) respectively. Then, the secondary antibody peroxidase-conjugated goat anti-rabbit IgG (catalog no ZB2301,ZSGB-BIO,Beijing,China) were added at 37°C for 1 hour. Then, the color was displayed with DAB (catalog no ZLI9018, ZSGB-BIO, Beijing, China), and counterstained with hematoxylin. The score system about data expression was calculated according to the reported method with Image J software, Unite Status [23].

2.9 Western blotting

Antibodies for α-tublin (catalog no 1122-1-AP,), NF-κBp65 (catalog no 66535-1-LG, Proteintech) and Beclin-1(catalog no ab207612, Abcam) and LC3B(catalog no ab48394, Abcam) were purchased from Unite Status. The procedures were conducted according to manufacturer’s protocol. In brief, the retrieved protein was loaded on SDS-PAGE gel. Next, the protein was transferred to polyvinylidene fluoride membranes (Millipore), and the membranes were incubated with primary antibody (1:1000) against NF-κBp65 at 4°C temperatures overnight. Subsequently, the secondary antibody incubation was conducted with goat anti-rabbit IgG antibody (catalog no 2B2301, ZSGB,China)(1:5000) for 1 h at 4°C temperatures. Finally, the intensity of band was calculated by NIH Image J software, Unite Status.

2.10 Quantitative polymerase chain reaction (Q-PCR) analysis

The total RNA extraction was conducted using Trizol Reagent (catalog no 15596026, Ambion, Unite States) in lung tissue. mRNA was reverse-transcripted to cDNA using 5'iScript. RT. Supermix kit (catalog no 64142209, Ambion, Unite States) according to the manufacturer’s instructions. House-keeping gene 18s was used as reference.
In C57BL/6J WT mice, the primer sequences used for qRT-PCR are as follows (from forward to reverse):
- **IL-6**: 5’-CTTCTTGGGACTGATGCTGGT-3’ and 5’-GACTCCAGTTATCTCTTGCTTG-3’
- **TNF-α**: 5’-CGGGCAGGTCTACTTTGGAG-3’ and 5’-ACCCTGACATGCACCCACCC-3’
- **Beclin-1**: 5’-AGCCTCTGAAACTGGACACG-3’ and 5’-ATGGCTCCTCTCCTGTAGA-3’
- **LC3B**: 5’-GGTTTATGCCTCGCAGGAGA-3’ and 5’-CTGAGTGAAAGGGTGTGGCT-3’
- **IFNα**: 5’-TCAAGCCATCCCTGTCCTACA-3’ and 5’-TCCTGCATCACACAGGCTTA-3’
- **IFNβ**: 5’-CCTGGAGCAGCTGAATGGAA-3’ and 5’-GAGTCCGCCTCTGATGCTTA-3’
- **IFNγ**: 5’-TGGAGGAACTGGCAAAAGGA-3’ and 5’-CACTGCAGCTCTGAATGTTTACTAT-3’
- **18s**: 5’-TTGACTCAACACGGGAAACC-3’ and 5’-AGACAAATCGCTCCACCAAC-3’

**2.11 Statistical analysis**

All results were expressed as Mean ± standard error mean (SEM). Data were analyzed by IBM SPSS 22.0 software. One-way ANOVA and Student t-test were used to determine the differences among all groups. P values <0.05 was considered as statistically significant.

**3. Results**

### 3.1 5.0mg/kg Nox1/4 inhibitor pretreatment attenuated LIRI

As shown in Fig 1A, there was no obvious difference in histological analysis among sham, 2.5 Nox+sham and 5.0 Nox+sham groups, but clear changes were observed in alveolar congestion, hemorrhage, interstitial edema, neutrophil count, and alveolar wall thickness in corresponding treatment IR groups. However, compared with 2.5mg/kg, 5.0mg/kg Nox1/4 inhibitor pretreatment significantly alleviated the acute damage from LIRI in lung injury score (Fig 1A and 1B). TUNEL staining also proved that LIRI induced to apoptosis of pulmonary tissue in the IR group, but it could be palliated by 5.0mg/kg Nox1/4 inhibitor pretreatment via reducing TUNEL-positive cells. Furthermore, in three sham groups (sham, 2.5Nox+sham, 5.0Nox+-sham), the number of TUNEL-positive cells was almost invisible, while a number of TUNEL-positive cells were shown in IR group which could not be alleviated by 2.5mg/kg Nox1/4 inhibitor pretreatment (Fig 1C and 1D). Thus, 5.0mg/kg Nox1/4 inhibitor pretreatment was considered as the minimal dose to attenuate LIRI.

### 3.2 Nox1/4 inhibitor pretreatment improved PH values and PaO$_2$/FiO$_2$ ratio

Male C57BL/6J WT mice were pretreated with 5.0mg/kg Nox1/4 inhibitors 30 minutes prior to IR as shown in Fig 2A. Compared with sham group, there was significant reduction in PH values (7.236 ± 0.241 vs. 7.119 ± 0.147, P<0.05) in IR group, but no difference in PaO$_2$/FiO$_2$ ratio (618 ± 15 vs. 550 ± 11, P = 0.053) (Fig 3A and 3B). Reduction of PH values were obviously reversed by 5.0mg/kg Nox1/4 inhibitor pretreatment (Fig 3A), and PaO$_2$/FiO$_2$ ratio showed an increased trend without statistical difference (Fig 3B).
3.3 Nox1/4 inhibitor pretreatment prevented NF-κBp65, TNFα and IL-6 activation after LIRI

The two kinds of technologies were applied to determine that NF-κBp65 and TNF-α activation were prevented after 5.0mg/kg Nox1/4 inhibitor pretreatment in LIRI (Fig 4A–4F). As shown in Fig 4A, 4D and 4F, NF-κBp65 and TNF-α immunohistochemistry staining expression were higher in IR and 5.0Nox+IR group compared with the sham group. 5.0mg/kg Nox1/4 inhibitor pretreatment significantly decreased the level NF-κBp65 in lung tissue, which were confirmed by western blotting test (Fig 4C and 4E). In contrast, 5.0mg/kg Nox1/4 inhibitor pretreatment...
Fig 4. Effects of 5.0mg/kg Nox1/4 inhibitor pretreatment on NF-κBp65, TNF α and IL-6 after LIRI. (A) Immunohistochemical staining (×400) of lung NF-κBp65 and TNF α; (B) The mRNA expression levels of TNF α in lung tissue after LIRI by Q-PCR analysis; (C) Representative Western blotting of NF-κBp65; (D) Calculating area ratio of TNF α in Immunohistochemical staining by Image J software; (E) The protein expression of NF-κBp65 in lung tissue after LIRI by western blotting; (F) Calculating area ratio of NF-κBp65 in Immunohistochemical staining by Image J software; (G) The mRNA expression levels of IL-6 in lung tissue after LIRI by Q-PCR analysis. Data were expressed as Mean ± SEM (n = 6~8) and compared by one-way ANOVA. *P<0.05 vs. sham group; **P<0.005 vs. sham group; ***P<0.0001 vs. sham group; #. 

https://doi.org/10.1371/journal.pone.0209444.g004
did not significantly reduce TNF-α expression in immunohistochemical assays, except for a downward trend. However, this difference was confirmed by the subsequent Q-PCR analysis which was more accurate (Fig 4B and 4D). Moreover, IL-6 mRNA concentration in IR group was higher than those of sham and 5.0Nox+IR groups (Fig 4G).

3.4 Nox1/4 inhibitor pretreatment prevented LIRI-induced autophagy activity in lung tissue

To demonstrate whether Nox1/4 Inhibitor pretreatment associated with autophagy induced by LIRI, the expression level of LC3B and Beclin-1 were tested in this study. The results determined that both LC3B and Beclin-1 were significantly increased after LIRI in lung tissue, while they could be reduced by 5.0mg/kg Nox1/4 Inhibitor pretreatment (Fig 5A, 5B and 5C). The results indicated that 5.0mg/kg Nox1/4 Inhibitor may confer lung protective effect via inhibiting autophagy activation.

3.5 Effects of Nox1/4 inhibitor disposal on immune related cytokines IFN α, IFN β and IFNγ

A previous study had proved IFN α and IFN β expression increased in inflammatory setting induced by hypoxia [24]. The expression of IFNγ was decreased when lung warm ischemia reperfusion injury was attenuated [25]. Q-PCR analysis demonstrated a significant upregulation IFN α, IFN β and IFNγ (7.32 ± 0.75, 2.30 ± 0.16 and 1.77 ± 0.00 fold respectively) after 60 minutes ischemia and 120 minutes reperfusion (Fig 6A, 6B and 6C), and 5.0mg/kg Nox1/4 inhibitor pretreatment dramatically decreased the levels of them. The above results confirmed that the lung protective effects of Nox1/4 inhibitor may be regulated via the regulation of immune function.

4. Discussion

In the current study, we tested whether different dose of Nox1/4 inhibitors had a different function in the progress of lung ischemia reperfusion injury in mice model. Our finding demonstrated that 5.0mg/kg Nox1/4 inhibitors pretreatment could mitigate lung injury after ischemia and reperfusion, while 2.5mg/kg had no significant lung protective effects. Histopathological and apoptosis results showed a significant lung injury after ischemia and reperfusion, but they were palliated by pretreatment of 5.0mg/kg Nox1/4 inhibitors. The benefit of 5.0mg/kg Nox1/4 inhibitor was further verified by improving acidosis and downregulating of inflammation and autophagy cytokines expression. In addition, IFN α and IFN β and IFNγ, involving the regulation of pro-inflammatory cytokines [24], were significantly upregulated after LIRI, but those trends were also controlled by 5.0mg/kg Nox1/4 inhibitor disposal. The present study showed a potential interrelationship between Nox1/4 inhibitor pretreatment and the progress of LIRI.

It was well known that LIRI involved a series of pathological reactions including oxidative stress, inflammation, autophagy and innate immunity [2, 26, 27]. Increasing evidence showed ROS generated by Nox could lead to inflammatory damage through the expression of transcription activator and inflammatory factors, including NF-κB p65, IL-6 and TNFα. Nox4 KO reduced infract size after cardiac ischemia-reperfusion and Nox1/4 inhibitor administration played anti-inflammation via reducing ROS level in ischemia retina [28, 29]. Over-production of ROS had been proven to involve LIRI and inflammatory processes [30]. The severity of lung injury was assessed by alveolar congestion, hemorrhage, interstitial edema, neutrophil count and alveolar wall thickness [20, 21]. Indeed, that Nox1/4 inhibitor was a kind of substance to
Fig 5. Effects of 5.0mg/kg Nox1/4 inhibitor pretreatment on LC3B and Beclin-1 mRNA expression after LIRI. (A) The mRNA expression levels of LC3B in lung tissue after LIRI by Q-PCR analysis; (B) The mRNA expression levels of Beclin-1 in lung tissue after LIRI by Q-PCR analysis; (C) The protein expression of Beclin-1 and LC3B in lung tissue after LIRI by western blotting. Data were expressed as Mean ± SEM (n = 6~8) and compared by one-way ANOVA. *P<0.05 vs. sham group; &P<0.05 vs. sham group or 5.0Nox+IR group; **P<0.005 vs. sham group or 5.0Nox+IR group; ***P<0.005 vs. 5.0Nox+IR group.

https://doi.org/10.1371/journal.pone.0209444.g005
avoid ROS generation was well-known, but whether the benefit of it could extend to protect LIRI and the minimal dose were poorly understood. According to existing literature, the dose of Nox1/4 inhibitor to inhibit NADPH-dependent ROS production could be ranging from 5–60 mg/kg p.o [31]. However, because of the higher bioavailability by i.p, we started the dose from 2.5 mg/kg in order to obtain the minimal dose for mitigating LIRI. Consisted with previous research, our data also confirmed that 5.0 mg/kg Nox1/4 inhibitor administration apparently reduced lung injury score and cell apoptosis. Thus, we proposed that 5.0mg/kg Nox1/4 inhibitor was a minimal dose in attenuating LIRI. However, the above results were not enough to prove the lung protective effects by Nox1/4 inhibitor. Next, we further explored the lung protective effects of 5.0mg/kg Nox1/4 inhibitor through molecular mechanisms. Fortunately,
we also determined the level of NF-κB, TNFα, IL-6 was dramatically upregulated after LIRI and downregulated after 5.0mg/kg pretreatment respectively. All of above results proved 5.0 mg/kg Nox1/4 inhibitor pretreatment had the effects of anti-inflammation in LIRI model.

Hypercapnic was not easily avoided after LIRI or long-time mechanical ventilation. Kavanagh’s group first demonstrated the benefit effects of hypercapnic after LIRI in the isolated rat lung [32]. However, there was no consensus on an acceptable lower limit for pH value. Compared with other groups, our study showed the lower PH value in IR group with more severe lung injury. The contradiction may due to limited PH value with protective effect, and beyond it may have opposite effects. Thus, we speculated moderate hypercapnic had protective effects after LIRI, but more severe hypercapnic would reduce or eliminate the benefits, which was similar with previous study [33]. Therefore, further experiments should be conducted to obtain the lowest protective PH value. Moreover, it was well known the serious LIRI was always accompanied pulmonary dysfunction. In clinical practice, PaO$_2$/FiO$_2$ ratio was an indicator to reflect the severity of lung injury. Interestingly, PaO$_2$/FiO$_2$ did not show any statistical difference between three groups in this study, only with a decreasing trend in IR group. We attributed it to the pulmonary function was still within compensative scope, even after ischemia-reperfusion, which was similar in clinical practice [34].

Moreover, we also observed the expression of IFNα and IFNβ obviously increased after 3h ischemia-reperfusion, compared with Nox1/4 inhibitor pretreatment group in this experiment. As mentioned in existed research, type-1 IFNs, including IFNα and IFNβ, could induce pro-inflammation resulting in secretion of inflammatory cytokines. Minter and his colleagues found increasing type-1 IFN deteriorated the hypoxic-ischemic injury outcomes in neuro cells [24], which implied IFNα and IFNβ may involve in inflammatory activation. We proposed ROS may also associate with it, because Nox1/4 inhibitor could decrease the level of IFNα and IFNβ dramatically. Furthermore, Martens et al. reported that the level of IFNy was increased after lung warm ischemia reperfusion injury [25]. In our study, the similar trend was observed. However, little was known about the potential mechanism. More research was needed to illuminate the relationship among IFNα, IFNβ, IFNγ and secretion of inflammatory cytokines.

Although a great deal of work had been devoted to investigate the role of autophagy in LIRI, it remained many controversies about the exact role of autophagy. Autophagy, as a normal physiological process, was regarded as involving degradation of cytoplasmic protein and molecules by autolysosome. Emerging evidence had proved dysfunction of autophagy was associated with ameliorating LIRI [35]. Correspondingly, over-expression of autophagy had a relationship with enhancing lung cell apoptosis [36], which was demonstrated in CPR and LIRI processes [37]. The expression of LC3B and Beclin-1, both as definitive autophagy biomarkers, were increased after lung transplantation which also was involved in LIRI in rats [36]. The level of LC3B and Beclin-1 increased at 3 hours after lung transplantation, achieved peak point at 6 hours and then decreased [38]. In our study, we also found the excessive protein and mRNA expression of LC3B and Beclin-1 after 3h LIRI and then dramatically inhibited by pretreatment 5.0mg/kg Nox1/4 inhibitor, which signified excessive autophagy may be restricted by pretreatment 5.0mg/kg Nox1/4 inhibitor in mice LIRI model.

Furthermore, although chloral hydrate for anesthesia or euthanasia was un-recommended by international laboratory animal science/veterinary entities as it was regarded to produce sedation rather than anesthesia and caused marked respiratory depression [39], we chose Intraperitoneal injection of 10% chloral hydrate 0.3 ml/100 g combined with 0.03mg/kg fentanyl, which offered good analgesic potency and sedation for mice. Opioids were usually combined with tranquilizers so that the amount of tranquilizer needed for heavy sedation could be reduced, decreasing unwanted side effects [40]. Another important reason was that 10%
chloral hydrate had been used in our previous research. We still chose it for sedation in order to minimize multiple exposures and balance with previous studies, but we combined with fentanyl for analgesia for minimizing mouse suffering. Moreover, in our study procedure, the anesthetized mice received mechanical ventilation immediately, so the respiratory depression was not a big issue. In the future, we will pay much more attention to the euthanasia issues and scientific animal welfare methods.

There also had some limitations in our study. We did not test the change of expression of Nox1 and Nox4 after LIRI. Although G137831 was a kind of dual inhibitor of Nox1 and Nox4 [29], the degree of inhibition was unknown in mice LIRI model. In addition, the detailed mechanisms should be investigated to clarify how Nox1/4 inhibitor played the protective effects in LIRI. In further research, we will focus on the underlying mechanisms not only on decreasing inflammatory and autophagy cytokines, but also the potential pathway of oxidative stress and innate immunity.

5. Conclusions
In conclusion, 5.0mg/kg Nox1/4 inhibitor can alleviate LIRI by downregulating the expression of inflammatory and autophagy cytokines. The apoptosis also has been inhibited after administration of Nox1/4 inhibitor. The innate immune and oxidative stress may also involve in the lung-protective mechanisms, but further research should be conduct to explore the potential pathways on how Nox1/4 inhibitor contributes to lung-protective effects.

Acknowledgments
We thank Yan Cheng, Sichuan University, Chengdu, China for providing technical support.

Author Contributions
Conceptualization: Yu Cui, Yu Wang, Bin Liu.
Data curation: Gen Li, Wan Ma, Bin Liu.
Formal analysis: Jia Wang.
Funding acquisition: Bin Liu.
Methodology: Yu Cui, Yu Wang, Jia Wang.
Project administration: Yu Wang, Xiao-shuang Zhou, Bin Liu.
Resources: Yu Cui, Bin Liu.
Software: Yu Wang, Wan Ma, Jia Wang.
Supervision: Bin Liu.
Validation: Bin Liu.
Visualization: Wan Ma, Bin Liu.
Writing – original draft: Yu Cui, Yu Wang.
Writing – review & editing: Gen Li, Xiao-shuang Zhou, Bin Liu.

References
1. Gielis JF, Beckers PAJ, Briede JJ, Cos P, Van Schil PE. Oxidative and nitrosative stress during pulmonary ischemia-reperfusion injury: from the lab to the OR. Ann Transl Med. 2017, 5(6):131. https://doi.org/10.21037/atm.2017.03.32 PMID: 28462211
2. Laubach VE, Sharma AK. Mechanisms of lung ischemia-reperfusion injury. Current Opinion in Organ Transplantation. 2016, 21:246–52. https://doi.org/10.1097/MOT.0000000000000034 PMID: 26945320

3. Fard N, Saffari A, Emami G, Hofer S, Kauczor HU, Mehrabi A. Acute respiratory distress syndrome induction by pulmonary ischemia-reperfusion injury in large animal models. J Surg Res 2014, 189 (2):274–84. https://doi.org/10.1016/j.jss.2014.02.034 PMID: 24768138

4. Kaaji NP, Kluin J, Hailsma JJ, Bakker MA, Lambrecht BN, Lachmann B, et al. Ischemia of the lung causes extensive long-term pulmonary injury: an experimental study. Respir Res 2008;26; 9:28. https://doi.org/10.1186/1465-9921-9-28 PMID: 18366783

5. Ferrari RS, Andrade CF. Oxidative Stress and Lung Ischemia-Reperfusion Injury. Oxidative medicine & cellular longevity 2015, 2015:590987. https://doi.org/10.1155/2015/590987 PMID: 26161240

6. Kreisel D, Goldstein DR. Innate immunity and organ transplantation: focus on lung transplantation. Transpl Int 2013, 26(1):2–10. https://doi.org/10.1111/j.1432-2277.2012.01549.x PMID: 22909350

7. Porteous MK, Diamond JM, Christie JD. Primary graft dysfunction: lessons learned about the first 72 h after lung transplantation. Curr Opin Organ Transplant 2015; 20(5):506–14. https://doi.org/10.1097/MOT.0000000000000232 PMID: 26262465

8. Liu ZH, Ou M, Yu LL, Song PP, Chang YL. Artesunate inhibits renal ischemia-reperfusion-mediated remote lung inflammation through attenuating ROS-induced activation of NLRP3 inflammasome. Inflammation 2018; 5. https://doi.org/10.1007/s10753-018-0801-z PMID: 29730819

9. Al-Mehdi AB, Shuman H, Fisher AB. Intracellular generation of reactive oxygen species during nonhypoxic lung ischemia. American Journal of Physiology—Lung Cellular and Molecular Physiology 1997; 272(2):294–300

10. Sun QC, Wu Y, Zhao F, Wang JJ. Maresin 1 Ameliorates Lung Ischemia/Reperfusion Injury by Suppressing Oxidative Stress via Activation of the Nrf-2-Mediated HO-1 Signaling Pathway. Oxidative medicine & cellular longevity 2017; 2017:9634803. https://doi.org/10.1155/2017/9634803 PMID: 28751936

11. Ovechkin AV, Lominadze D, Sedoris KC, Robinson TW, Tyagi SC, Roberts AM. Lung ischemia-reperfusion injury: implications of oxidative stress and platelet-arteriolar wall interactions. Arch Physiol Biochem 2007; 113(1):1–12. https://doi.org/10.1080/1381345060118976 PMID: 17522980

12. Aviello G, Knaus UG. NADPH oxidases and ROS signaling in the gastrointestinal tract. Mucosal Immunol 2018; 9. https://doi.org/10.1038/s41385-018-0021-8 PMID: 29743690

13. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011; 10:453–71. https://doi.org/10.1038/nrd3403 PMID: 21629295

14. Csanyi G, Taylor WR, Pagano PJ. NOX and inflammation in the vascular adventitia, Free Radic. Biol. Med.2009; 47(9):1254–1266. https://doi.org/10.1016/j.freeradbiomed.2009.08.003

15. Li Y, Pagano PJ. Microvascular NADPH oxidase in health and disease. Free Radic Biol Med. 2017; 109:33–47. https://doi.org/10.1016/j.freeradbiomed.2017.02.049 PMID: 28274817

16. Yokota H, Tsuzuki A, Shimada Y. NOX1/NADPH Oxidase Expressed in Colonic Macrophages Contributes to the Pathogenesis of Colonic Inflammation in Trinitrobenzene Sulfonic Acid Induced Murine Colitis. J Pharmacol Exp Ther. 2017; 360(1):192–200. https://doi.org/10.1124/jpet.116.235580 PMID: 27754929

17. Sakai Y, Yamamoto T, Yoshikawa Y, Bo T, Suzuki M, Yamamoto K, et al. NADPH oxidase 4 mediates ROS production in radiation-induced senescent cells and promotes migration of inflammatory cells. Free Radic Res.2018; 52(1):92–102. https://doi.org/10.1080/10715762.2017.1416112 PMID: 29229832

18. Deliyaniti D, Wilkinson-Berkia JL. Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina. J Neuroinflammation. 2015; 10:123. https://doi.org/10.1186/s12974-015-0363-z

19. Steven L, Wendy U, Raymond A, Samuel C, Douglas C, Temple G, et al. AVMA guidelines for the euthanasia of animals; 2013 edition. Schaumburg (IL): American Veterinary Medical Association; 2013.

20. Fard N, Saffari A, Emami G, Hofer S, Kauczor HU, Mehrabi A. Acute respiratory distress syndrome induction by pulmonary ischemia-reperfusion injury in large animal models. The Journal of surgical research. 2014; 189(2):274–84. https://doi.org/10.1016/j.jss.2014.02.034 PMID: 24768138

21. Nemery B, Vanlommel S, Verbekeent EK, Lauweryns JM, Demedts M. Lung injury induced by paraquat hyperoxia and cobalt chloride effects of ambroxol. Pulmonary Pharmacology. 1992; 5(1):53–60 PMID: 15914642

22. Ge M, Chen C, Yao W, Zhou S, Huang F, Cai J, et al. Overexpression of brg1 alleviates hepatic ischemia/reperfusion-induced acute lung injury through antioxidative stress effects. Oxid Med Cell Longev. 2017; 2017:8787392. https://doi.org/10.1155/2017/8787392 PMID: 28798861
23. Lunardi F, Zampieri D, Vadorti M, Bernardi D, Vuljan S, Nannini N, et al. Overexpression of Hypoxia-Inducible Factor-1alpha in Primary Graft Dysfunction Developing in an Orthotopic Lung Transplantation Rat Model. Transplant Proc. 2017; 49(4):722–725. https://doi.org/10.1016/j.transproceed.2017.02.037 PMID: 28457380

24. Minter MR, Zhang M, Ates RC, Taylor JM, Crack PJ. Type-1 interferons contribute to oxygen glucose deprivation induced neuro-inflammation in BE(2) M17 human neuroblastoma cells. Journal of Neuroinflammation. 2014; 11:43. https://doi.org/10.1186/1742-2094-11-43 PMID: 24602263

25. Martens A, Boada M, Vanaudenaerde BM, Verleden SE, Vos R, Verleden GM. Steroids can reduce warm ischemic reperfusion injury in a porcine donation after circulatory death model with ex vivo lung perfusion evaluation. Transpl Int. 2016; 29(11):1237–1246. https://doi.org/10.1111/tri.12823 PMID: 27514498

26. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol. 2010; 10:826–837. https://doi.org/10.1038/nri2873 PMID: 21088683

27. Gielis JF, Boulet GA, Briede JJ, Horemans T, Debergh T, Kusse M, et al. Longitudinal quantification of radical bursts during pulmonary ischaemia and reperfusion. Eur J Cardiothorac Surg. 2015; 48:622–629. https://doi.org/10.1093/ejcts/ezu518 PMID: 25564212

28. Matsushima S, Kuroda J, Ago T, Zhai P, Ikeda Y, Oka S, et al. Broad suppression of NADPH oxidase activity exacerbates ischemia/reperfusion injury through inadvertent downregulation of hypoxia-inducible factor-1alpha and upregulation of peroxisome proliferator-activated receptor-alpha. Circ Res. 2013; 112:1135–1149. https://doi.org/10.1161/CIRCRESAHA.111.300171 PMID: 23476056

29. Deliyanti D, Wilkinson-Berka JL. Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina. J Neuroinflammation. 2015; 30(12):136. https://doi.org/10.1186/s12974-015-0363-z

30. Demiryurek AT, Wadsworth RM. Superoxide in the pulmonary circulation. Pharmacol Ther. 1999; 84:355–65. PMID: 10665834

31. Teixeira G, Szynrdalewicz C, Molango S, Carnesecchi S, Heitz F, Wiesel P, et al. Therapeutic potential of NOX1/4 inhibitors. Br J Pharmacol. 2017; 174(12):1647–1669. https://doi.org/10.1111/bjp.13532 PMID: 27273790

32. Shibata K, Cregg N, Engelberts D, Takeuchi A, Fedorko L, Kavanagh BP. Hypercapnic acidosis may attenuate acute lung injury by inhibition of endogenous xanthine oxidase. Am J Respir Crit Care Med. 1998; 158:1578–1584. https://doi.org/10.1164/ajrccm.158.5.9804039 PMID: 9817711

33. Ansari B, Laffey JG. Ischemia-reperfusion-induced lung injury: could hypercapnia have a therapeutic role? Crit Care Med. 2012; 40(2):688–90. https://doi.org/10.1097/CCM.0b013e3182372b7e PMID: 22249055

34. Padilla J, Calvo V, Pastor J, Blasco E, París F. Single-lung transplant and primary graft failure. Arch Bronconeumol. 2002; 38(1):16–20. PMID: 11809132

35. Zhang D, Li C, Song Y, Zhou J, Li Y, Li J, Bai C. Integrin alphav beta 5 inhibition protects against ischemia-reperfusion-induced lung injury in an autophagy-dependent manner. Am J Physiol Lung Cell Mol Physiol. 2017; 313(2):L384–L394. https://doi.org/10.1152/ajplung.00391.2016 PMID: 28522565

36. Liu S, Zhang J, Yu BT, Huang L, Dai B, Liu JC, et al. The role of autophagy in lung ischemia/reperfusion injury after lung transplantation in rats. Am J Transl Res. 2016; 8(8):3593–3602 PMID: 27648150

37. Ma Y, Chen C, Zhang S, Wang Q, Chen H, Dong Y, et al. RNase alleviates neurological dysfunction in mice undergoing cardiac arrest and cardiopulmonary resuscitation. Oncotarget, 2017; 8(32):53084–53099. https://doi.org/10.18632/oncotarget.18088 PMID: 28881795

38. Chen X, Wu JX, You XJ, Zhu HW, Wei JL, Xu MY. Cold ischemia-induced autophagy in rat lung tissue. Mol Med Rep. 2015; 11(4):2513–2519. https://doi.org/10.3892/mmr.2014.2999 PMID: 25435100

39. Baxter MG, Murphy KL, Taylor PM, Wolfensohn SE. Chloral Hydrate Is Not Acceptable for Anesthesia or Euthanasia of Small Animals. Anesthesiology. 2009; 111(1):209. https://doi.org/10.1097/ALN.0b013e3181a8617e PMID: 19546703

40. Lukasik VM, Gillies RJ. Animal anaesthesia for in vivo magnetic resonance. NMR Biomed. 2003; 16:459–467 https://doi.org/10.1002/nbm.836 PMID: 14696002